Eli Lilly price target raised to $1,400 from $1,300 at JPMorgan
JPMorgan raised the firm's price target on Eli Lilly to $1,400 from $1,300 and keeps an Overweight rating on the shares. The firm sees potential upside for Mounjaro from growth in the U.S. obesity market and internationally, the analyst tells investors in a Q2 earnings preview.